Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

• Status: Completed
• Trial end date: 2019-04-24

Summary

The purpose of this study is to assess the efficacy and safety of Ravidasvir in combination with Danoprevir/r and ribavirin(RBV) by sustain virologic response 12 (SVR12), in treatment-naive, non-cirrhotic, chronic hepatitis C genotype 1 infected patients.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.
• Treatments: Lactams; Ribavirin; Ritonavir